Multiple markers contribute to risk of progression from normal to mild cognitive impairment

Jennifer S. Rabin, Taylor E. Neal, Hannah E. Nierle, Sietske A.M. Sikkes, Rachel F. Buckley, Rebecca E. Amariglio, Kathryn V. Papp, Dorene M. Rentz, Aaron P. Schultz, Keith A. Johnson, Reisa A. Sperling, Trey Hedden

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objective: To identify a parsimonious set of markers that optimally predicts subsequent clinical progression from normal to mild cognitive impairment (MCI). Methods: 250 clinically normal adults (mean age = 73.6 years, SD = 6.0) from the Harvard Aging Brain Study were assessed at baseline on a wide set of markers, including magnetic resonance imaging markers of gray matter thickness and volume, white matter lesions, fractional anisotropy, resting state functional connectivity, positron emission tomography markers of glucose metabolism and β-amyloid (Aβ) burden, and a measure of vascular risk. Participants were also tested annually on a battery of clinical and cognitive tests (median follow-up = 5.0 years, SD = 1.66). We applied least absolute shrinkage and selection operator (LASSO) Cox models to determine the minimum set of non-redundant markers that predicts subsequent clinical progression from normal to MCI, adjusting for age, sex, and education. Results: 23 participants (9.2%) progressed to MCI over the study period (mean years of follow-up to diagnosis = 3.96, SD = 1.89). Progression was predicted by several brain markers, including reduced entorhinal thickness (hazard ratio, HR = 1.73), greater Aβ burden (HR = 1.58), lower default network connectivity (HR = 1.42), and smaller hippocampal volume (HR = 1.30). When cognitive test scores were added to the model, the aforementioned neuroimaging markers remained significant and lower striatum volume as well as lower scores on baseline memory and processing speed tests additionally contributed to progression. Conclusion: Among a large set of brain, vascular and cognitive markers, a subset of markers independently predicted progression from normal to MCI. These markers may enhance risk stratification by identifying clinically normal individuals who are most likely to develop clinical symptoms and would likely benefit most from therapeutic intervention.

Original languageEnglish
Article number102400
JournalNeuroImage: Clinical
StatePublished - 2020


  • Aging
  • Alzheimer's disease
  • Amyloid
  • Clinical Dementia Rating
  • Memory
  • Mild cognitive impairment
  • Neuroimaging
  • Survival


Dive into the research topics of 'Multiple markers contribute to risk of progression from normal to mild cognitive impairment'. Together they form a unique fingerprint.

Cite this